Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

in adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT). Results demonstrated an overall response rate ...

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

Jeremy S. Abramson, MD, discusses the significant 2-year follow-up results from the phase 3 STARGLO trial in DLBCL.